Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)
Source: SeekingAlpha
2025-10-13 14:35:33 ET
Shares of mast cell therapy concern Celldex Therapeutics, Inc. ( CLDX ) have rallied just over 70% off their 60-month April 2025 low that was caused by high discontinuation rates for lead asset barzolvolimab. The company’s only significant candidate has demonstrated best-in-class efficacy in chronic spontaneous urticaria, which it is trying to replicate in two Phase 3 studies that are now enrolling. With an operating runway through 2027, good enough to get it through four needle-moving studies in increasingly competitive indications, Celldex merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade)
Novartis Ag Basel Akt
NASDAQ: NVSEF
NVSEF Trading
0.0% G/L:
$151 Last:
408 Volume:
$151 Open:
NVSEF Latest News
February 25, 2026 07:00:00 am
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next?generation treatments to patients
February 06, 2026 12:00:00 pm
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
January 09, 2026 10:30:00 am
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
December 12, 2025 07:00:00 am
Novartis breaks ground on flagship manufacturing hub in North Carolina
NVSEF Stock Data
$299,675,221,187
2,118,043,712
N/A
1352
N/A
Pharmaceuticals
Healthcare
CH
Basel
